atenolol has been researched along with Liver Diseases in 3 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver." | 2.36 | Clinical pharmacokinetics of atenolol--a review. ( Görg, KG; Kirch, W, 1982) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " Thus, plasma half-life after intravenous dosing of atenolol was 6." | 1.27 | Clinical experience with atenolol in patients with chronic liver disease. ( Braun, W; Kirch, W; Mutschler, E; Ohnhaus, EE; Schäfer-Korting, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Kirch, W | 2 |
| Görg, KG | 1 |
| Schäfer-Korting, M | 1 |
| Mutschler, E | 1 |
| Ohnhaus, EE | 1 |
| Braun, W | 1 |
1 review available for atenolol and Liver Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics of atenolol--a review.
Topics: Administration, Oral; Atenolol; Biological Availability; Drug Interactions; Humans; Injections, Intr | 1982 |
2 other studies available for atenolol and Liver Diseases
| Article | Year |
|---|---|
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Clinical experience with atenolol in patients with chronic liver disease.
Topics: Administration, Oral; Adult; Atenolol; Chronic Disease; Female; Humans; Injections, Intravenous; Kid | 1983 |